Unfolding Reasoning Case Study: Heart Failure – JoAnn
Smith | Heart Failure Nursing Case Study & Clinical
Reasoning Review 2026/2027 | Adult Medical-Surgical
Nursing, Cardiac Assessment, Perfusion, Gas
Exchange, Fluid & Electrolyte Balance, Clinical
Judgment, Heart Failure Management, Nursing
Interventions, Patient Education, Care Planning, Case-
Based Practice & Detailed Rationales
Question 1: A 68-year-old female with a history of hypertension and type 2
diabetes presents with progressive dyspnea on exertion, orthopnea, and
bilateral lower extremity edema. Her jugular venous pressure is estimated at
14 cm H₂O, and an S3 gallop is auscultated. Which of the following
pathophysiological mechanisms is the PRIMARY driver of her elevated jugular
venous pressure?
A. Decreased renal perfusion leading to activation of the renin-angiotensin-aldosterone
system
B. Increased left ventricular end-diastolic pressure transmitted to the pulmonary
vasculature
C. Impaired right ventricular contractility leading to increased systemic venous
congestion
D. Reduced cardiac output causing compensatory sympathetic nervous system
activation
CORRECT ANSWER: B. Increased left ventricular end-diastolic pressure
transmitted to the pulmonary vasculature
Rationale: The patient's presentation is consistent with left-sided heart failure. The S3
gallop indicates elevated left ventricular filling pressures. This increased left ventricular
end-diastolic pressure (LVEDP) is transmitted retrograde through the pulmonary veins,
increasing pulmonary capillary wedge pressure. Over time, this leads to pulmonary
hypertension, which increases the afterload on the right ventricle. The elevated right
ventricular pressures are then transmitted back to the systemic venous circulation,
manifesting as an elevated jugular venous pressure. While options A, C, and D occur in
heart failure, they are not the primary direct cause of elevated JVP in a patient with
predominant left-sided failure; the retrograde transmission of pressure from the left
heart is the initiating and primary driver.
Question 2: JoAnn Smith is a 72-year-old female with chronic heart failure
with preserved ejection fraction (HFpEF). She is admitted with an acute
exacerbation. Her blood pressure is 160/90 mmHg, and she has significant
pulmonary edema. Which of the following medications is MOST appropriate
as a first-line agent to reduce preload and manage her acute hypertensive
crisis in this setting?
,A. Oral furosemide
B. Intravenous hydralazine
C. Sublingual nitroglycerin
D. Intravenous nitroprusside
CORRECT ANSWER: D. Intravenous nitroprusside
Rationale: In an acute hypertensive crisis with pulmonary edema, intravenous
nitroprusside is a potent vasodilator that effectively reduces both preload and afterload.
Its rapid onset and short half-life allow for precise titration to reduce blood pressure and
left ventricular filling pressures. Sublingual nitroglycerin is primarily a venodilator
(reducing preload) but is less effective for afterload reduction and may not be sufficient
for severe hypertension. Intravenous hydralazine is an afterload reducer but has a less
predictable onset and can cause reflex tachycardia. Oral furosemide is too slow for the
acute management of a hypertensive crisis with severe pulmonary edema.
Question 3: In the context of managing JoAnn Smith's chronic HFpEF, which of
the following comorbidities is MOST critical to aggressively manage to
improve her long-term outcomes and reduce hospitalizations?
A. Iron deficiency anemia
B. Chronic kidney disease stage 3
C. Systemic hypertension
D. Obstructive sleep apnea
CORRECT ANSWER: C. Systemic hypertension
Rationale: Hypertension is the most prevalent and critical comorbidity in patients with
HFpEF. Chronic pressure overload leads to left ventricular hypertrophy, increased
myocardial stiffness, and diastolic dysfunction, all of which are central to the
pathophysiology of HFpEF. Aggressive blood pressure control is the cornerstone of
management and has been shown to reduce the risk of heart failure hospitalizations in
this population. While anemia, CKD, and OSA are important comorbidities,
hypertension management has the most direct and significant impact on the underlying
pathophysiology and clinical outcomes in HFpEF.
Question 4: JoAnn Smith's heart failure exacerbation is thought to be due to
medication non-adherence. Which of the following medications, if suddenly
discontinued, would be MOST likely to cause a significant fluid retention and
decompensation in a patient with chronic heart failure?
A. Spironolactone
B. Furosemide
C. Lisinopril
D. Carvedilol
,CORRECT ANSWER: C. Lisinopril
Rationale: Sudden withdrawal of an angiotensin-converting enzyme inhibitor (ACEI) like
lisinopril can lead to a "rebound" phenomenon. ACEIs reduce angiotensin II and
aldosterone levels, promoting vasodilation and sodium excretion. Their abrupt cessation
can cause a rapid increase in angiotensin II, leading to profound vasoconstriction,
increased aldosterone secretion, and subsequent sodium and water retention. This can
precipitate acute decompensated heart failure. While diuretic and beta-blocker
withdrawal are also harmful, the rapid hemodynamic and neurohormonal effects of
ACEI withdrawal make it particularly dangerous for fluid retention and decompensation.
Question 5: During a routine follow-up, JoAnn Smith reports a persistent, dry,
hacking cough that has been bothering her for several months. She is on
lisinopril for her heart failure. What is the MOST appropriate next step in
managing this adverse effect?
A. Reassure the patient that the cough is benign and will subside with continued use
B. Add a cough suppressant to her current medication regimen
C. Discontinue lisinopril and switch to an angiotensin II receptor blocker (ARB)
D. Perform a chest X-ray to rule out a pulmonary infection
CORRECT ANSWER: C. Discontinue lisinopril and switch to an angiotensin II
receptor blocker (ARB)
Rationale: A persistent, dry cough is a well-known and classic side effect of ACE
inhibitors, occurring in up to 20% of patients. It is caused by the accumulation of
bradykinin in the pulmonary tissues. If the cough is bothersome and affects quality of
life, the most appropriate management is to discontinue the ACEI and switch to an ARB.
ARBs provide similar renin-angiotensin-aldosterone system (RAAS) blockade with a
significantly lower incidence of cough. The cough will not necessarily subside with
continued use, and cough suppressants are not effective. A chest X-ray would be
indicated if an infection or other pathology were suspected, but the temporal
relationship to the medication makes it the most likely cause.
Question 6: JoAnn Smith's ejection fraction is found to be 35%. In addition to
an ACE inhibitor and a beta-blocker, which of the following medication classes
provides the MOST significant mortality benefit specifically in this population
of patients with heart failure with reduced ejection fraction (HFrEF)?
A. Aldosterone antagonist
B. Digoxin
C. Hydralazine and isosorbide dinitrate
D. Calcium channel blocker
CORRECT ANSWER: A. Aldosterone antagonist
, Rationale: In patients with HFrEF (EF ≤ 35%), the addition of an aldosterone antagonist
(mineralocorticoid receptor antagonist), such as spironolactone or eplerenone, to
standard therapy with an ACEI/ARB and a beta-blocker, has been shown to provide a
significant reduction in mortality and hospitalizations (as seen in the RALES and
EMPHASIS-HF trials). While hydralazine and isosorbide dinitrate are beneficial,
especially in African American patients, the mortality benefit of aldosterone antagonists
is more broadly indicated for this specific EF threshold. Digoxin is for symptomatic
control and does not reduce mortality. Calcium channel blockers are generally not
recommended in HFrEF due to negative inotropic effects.
Question 7: JoAnn Smith is started on carvedilol. Which of the following is a
critical principle regarding the initiation and titration of this medication in a
patient with stable chronic heart failure?
A. It should be started at a high dose to achieve therapeutic levels quickly
B. It should be titrated to the maximum tolerated dose, usually every 2-4 weeks
C. It should be avoided if the patient has a history of asthma due to its beta-1 selectivity
D. It is primarily a diuretic and should replace furosemide once the dose is stable
CORRECT ANSWER: B. It should be titrated to the maximum tolerated dose,
usually every 2-4 weeks
Rationale: Beta-blockers like carvedilol are essential for HFrEF but have negative
inotropic effects. They must be started at very low doses and titrated slowly (e.g.,
doubled every 2-4 weeks) to the maximum tolerated dose. This slow up-titration allows
the heart to adapt and minimizes the risk of precipitating acute decompensation or
worsening heart failure. Carvedilol is a non-selective beta-blocker (beta-1, beta-2, and
alpha-1) and is contraindicated in patients with severe asthma or bronchospasm. It is
not a diuretic and does not replace loop diuretics.
Question 8: A patient with heart failure is noted to have a narrow pulse
pressure. This clinical finding is MOST indicative of:
A. Aortic regurgitation
B. High cardiac output state
C. Reduced stroke volume
D. Severe bradycardia
CORRECT ANSWER: C. Reduced stroke volume
Rationale: Pulse pressure is the difference between systolic and diastolic blood pressure.
It is a reflection of stroke volume and arterial compliance. A narrow pulse pressure (e.g.,
less than 25% of the systolic pressure) suggests a reduced stroke volume. In heart
failure, the failing heart cannot generate a large systolic pressure, and the reduced stroke
volume leads to a smaller difference between systolic and diastolic pressures. Aortic
Smith | Heart Failure Nursing Case Study & Clinical
Reasoning Review 2026/2027 | Adult Medical-Surgical
Nursing, Cardiac Assessment, Perfusion, Gas
Exchange, Fluid & Electrolyte Balance, Clinical
Judgment, Heart Failure Management, Nursing
Interventions, Patient Education, Care Planning, Case-
Based Practice & Detailed Rationales
Question 1: A 68-year-old female with a history of hypertension and type 2
diabetes presents with progressive dyspnea on exertion, orthopnea, and
bilateral lower extremity edema. Her jugular venous pressure is estimated at
14 cm H₂O, and an S3 gallop is auscultated. Which of the following
pathophysiological mechanisms is the PRIMARY driver of her elevated jugular
venous pressure?
A. Decreased renal perfusion leading to activation of the renin-angiotensin-aldosterone
system
B. Increased left ventricular end-diastolic pressure transmitted to the pulmonary
vasculature
C. Impaired right ventricular contractility leading to increased systemic venous
congestion
D. Reduced cardiac output causing compensatory sympathetic nervous system
activation
CORRECT ANSWER: B. Increased left ventricular end-diastolic pressure
transmitted to the pulmonary vasculature
Rationale: The patient's presentation is consistent with left-sided heart failure. The S3
gallop indicates elevated left ventricular filling pressures. This increased left ventricular
end-diastolic pressure (LVEDP) is transmitted retrograde through the pulmonary veins,
increasing pulmonary capillary wedge pressure. Over time, this leads to pulmonary
hypertension, which increases the afterload on the right ventricle. The elevated right
ventricular pressures are then transmitted back to the systemic venous circulation,
manifesting as an elevated jugular venous pressure. While options A, C, and D occur in
heart failure, they are not the primary direct cause of elevated JVP in a patient with
predominant left-sided failure; the retrograde transmission of pressure from the left
heart is the initiating and primary driver.
Question 2: JoAnn Smith is a 72-year-old female with chronic heart failure
with preserved ejection fraction (HFpEF). She is admitted with an acute
exacerbation. Her blood pressure is 160/90 mmHg, and she has significant
pulmonary edema. Which of the following medications is MOST appropriate
as a first-line agent to reduce preload and manage her acute hypertensive
crisis in this setting?
,A. Oral furosemide
B. Intravenous hydralazine
C. Sublingual nitroglycerin
D. Intravenous nitroprusside
CORRECT ANSWER: D. Intravenous nitroprusside
Rationale: In an acute hypertensive crisis with pulmonary edema, intravenous
nitroprusside is a potent vasodilator that effectively reduces both preload and afterload.
Its rapid onset and short half-life allow for precise titration to reduce blood pressure and
left ventricular filling pressures. Sublingual nitroglycerin is primarily a venodilator
(reducing preload) but is less effective for afterload reduction and may not be sufficient
for severe hypertension. Intravenous hydralazine is an afterload reducer but has a less
predictable onset and can cause reflex tachycardia. Oral furosemide is too slow for the
acute management of a hypertensive crisis with severe pulmonary edema.
Question 3: In the context of managing JoAnn Smith's chronic HFpEF, which of
the following comorbidities is MOST critical to aggressively manage to
improve her long-term outcomes and reduce hospitalizations?
A. Iron deficiency anemia
B. Chronic kidney disease stage 3
C. Systemic hypertension
D. Obstructive sleep apnea
CORRECT ANSWER: C. Systemic hypertension
Rationale: Hypertension is the most prevalent and critical comorbidity in patients with
HFpEF. Chronic pressure overload leads to left ventricular hypertrophy, increased
myocardial stiffness, and diastolic dysfunction, all of which are central to the
pathophysiology of HFpEF. Aggressive blood pressure control is the cornerstone of
management and has been shown to reduce the risk of heart failure hospitalizations in
this population. While anemia, CKD, and OSA are important comorbidities,
hypertension management has the most direct and significant impact on the underlying
pathophysiology and clinical outcomes in HFpEF.
Question 4: JoAnn Smith's heart failure exacerbation is thought to be due to
medication non-adherence. Which of the following medications, if suddenly
discontinued, would be MOST likely to cause a significant fluid retention and
decompensation in a patient with chronic heart failure?
A. Spironolactone
B. Furosemide
C. Lisinopril
D. Carvedilol
,CORRECT ANSWER: C. Lisinopril
Rationale: Sudden withdrawal of an angiotensin-converting enzyme inhibitor (ACEI) like
lisinopril can lead to a "rebound" phenomenon. ACEIs reduce angiotensin II and
aldosterone levels, promoting vasodilation and sodium excretion. Their abrupt cessation
can cause a rapid increase in angiotensin II, leading to profound vasoconstriction,
increased aldosterone secretion, and subsequent sodium and water retention. This can
precipitate acute decompensated heart failure. While diuretic and beta-blocker
withdrawal are also harmful, the rapid hemodynamic and neurohormonal effects of
ACEI withdrawal make it particularly dangerous for fluid retention and decompensation.
Question 5: During a routine follow-up, JoAnn Smith reports a persistent, dry,
hacking cough that has been bothering her for several months. She is on
lisinopril for her heart failure. What is the MOST appropriate next step in
managing this adverse effect?
A. Reassure the patient that the cough is benign and will subside with continued use
B. Add a cough suppressant to her current medication regimen
C. Discontinue lisinopril and switch to an angiotensin II receptor blocker (ARB)
D. Perform a chest X-ray to rule out a pulmonary infection
CORRECT ANSWER: C. Discontinue lisinopril and switch to an angiotensin II
receptor blocker (ARB)
Rationale: A persistent, dry cough is a well-known and classic side effect of ACE
inhibitors, occurring in up to 20% of patients. It is caused by the accumulation of
bradykinin in the pulmonary tissues. If the cough is bothersome and affects quality of
life, the most appropriate management is to discontinue the ACEI and switch to an ARB.
ARBs provide similar renin-angiotensin-aldosterone system (RAAS) blockade with a
significantly lower incidence of cough. The cough will not necessarily subside with
continued use, and cough suppressants are not effective. A chest X-ray would be
indicated if an infection or other pathology were suspected, but the temporal
relationship to the medication makes it the most likely cause.
Question 6: JoAnn Smith's ejection fraction is found to be 35%. In addition to
an ACE inhibitor and a beta-blocker, which of the following medication classes
provides the MOST significant mortality benefit specifically in this population
of patients with heart failure with reduced ejection fraction (HFrEF)?
A. Aldosterone antagonist
B. Digoxin
C. Hydralazine and isosorbide dinitrate
D. Calcium channel blocker
CORRECT ANSWER: A. Aldosterone antagonist
, Rationale: In patients with HFrEF (EF ≤ 35%), the addition of an aldosterone antagonist
(mineralocorticoid receptor antagonist), such as spironolactone or eplerenone, to
standard therapy with an ACEI/ARB and a beta-blocker, has been shown to provide a
significant reduction in mortality and hospitalizations (as seen in the RALES and
EMPHASIS-HF trials). While hydralazine and isosorbide dinitrate are beneficial,
especially in African American patients, the mortality benefit of aldosterone antagonists
is more broadly indicated for this specific EF threshold. Digoxin is for symptomatic
control and does not reduce mortality. Calcium channel blockers are generally not
recommended in HFrEF due to negative inotropic effects.
Question 7: JoAnn Smith is started on carvedilol. Which of the following is a
critical principle regarding the initiation and titration of this medication in a
patient with stable chronic heart failure?
A. It should be started at a high dose to achieve therapeutic levels quickly
B. It should be titrated to the maximum tolerated dose, usually every 2-4 weeks
C. It should be avoided if the patient has a history of asthma due to its beta-1 selectivity
D. It is primarily a diuretic and should replace furosemide once the dose is stable
CORRECT ANSWER: B. It should be titrated to the maximum tolerated dose,
usually every 2-4 weeks
Rationale: Beta-blockers like carvedilol are essential for HFrEF but have negative
inotropic effects. They must be started at very low doses and titrated slowly (e.g.,
doubled every 2-4 weeks) to the maximum tolerated dose. This slow up-titration allows
the heart to adapt and minimizes the risk of precipitating acute decompensation or
worsening heart failure. Carvedilol is a non-selective beta-blocker (beta-1, beta-2, and
alpha-1) and is contraindicated in patients with severe asthma or bronchospasm. It is
not a diuretic and does not replace loop diuretics.
Question 8: A patient with heart failure is noted to have a narrow pulse
pressure. This clinical finding is MOST indicative of:
A. Aortic regurgitation
B. High cardiac output state
C. Reduced stroke volume
D. Severe bradycardia
CORRECT ANSWER: C. Reduced stroke volume
Rationale: Pulse pressure is the difference between systolic and diastolic blood pressure.
It is a reflection of stroke volume and arterial compliance. A narrow pulse pressure (e.g.,
less than 25% of the systolic pressure) suggests a reduced stroke volume. In heart
failure, the failing heart cannot generate a large systolic pressure, and the reduced stroke
volume leads to a smaller difference between systolic and diastolic pressures. Aortic
